Axogen Inc - AXGN STOCK NEWS

Axogen, Inc. (NASDAQ: AXGN) announced that CEO Karen Zaderej will present at the Jefferies London Healthcare Conference on November 17, 2021, at 4:25 p.m. (11:25 a.m. ET). The presentation will be streamed live on the company's Investors page, with a replay available for 90 days. Axogen specializes in innovative surgical solutions for peripheral nerve injuries, aiming to restore nerve function and quality of life for patients. Their product portfolio includes Avance® Nerve Graft and Axoguard series, designed to effectively repair peripheral nerves.

Axogen, Inc. (NASDAQ: AXGN) reported Q3 2021 net revenue of $31.2 million, a 7% decline from $33.4 million in Q3 2020. The net loss increased to $7.1 million, or $0.17 per share, compared to a net loss of $1.5 million, or $0.04 per share, in the prior year. Despite lower procedure volumes due to COVID-19 challenges, gross margin improved to 83.2%. The company revised its 2021 revenue guidance to between $127 million and $129 million, down from the previous estimate of $134.5 million to $137.5 million.

Axogen (NASDAQ: AXGN) will report its third quarter 2021 financial results on November 3, 2021, after market close. Following this, management will host a conference call at 4:30 p.m. ET to discuss the results. Interested investors can participate via phone or listen to the webcast on the company's website. Axogen specializes in surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard Nerve Protector® to aid in nerve repair and regeneration, thus improving patients' quality of life.

Axogen, a leader in surgical solutions for peripheral nerve damage, will participate in the 76th Annual Meeting of the American Society for Surgery of the Hand (ASSH) from September 30-October 2, 2021 in San Francisco. The company will host a symposium on October 1, featuring an expert panel discussing the impact of Axogen technologies on nerve repair practices. Attendees can engage with Axogen scientists and explore innovative surgical techniques at Booth #950. Axogen will also support educational initiatives and offer travel scholarships for attendees.

Axogen announced the completion of subject follow-up for its pivotal RECON Clinical Study, supporting the Biologics License Application (BLA) for Avance® Nerve Graft. The study met its enrollment target of 220 subjects in July 2020 and is on track for a top-line data read-out in Q2 2022, followed by BLA submission in 2023. The RECON study aims to provide Level 1 clinical data, comparing Avance Nerve Graft to manufactured conduits in digital nerve injuries, focusing on recovery of sensation and quality of life outcomes.

Axogen, Inc. (NASDAQ: AXGN) reported a strong second quarter for 2021, with net revenue of $33.6 million, a 52% increase year-over-year. The company achieved a gross margin of 78.9%, boosted by a recovery in sales despite a $1.4 million one-time charge. While the net loss was $7.9 million ($0.19 per share), this showed improvement compared to the prior year. Additionally, Axogen updated its 2021 revenue guidance to a range of $134.5 million to $137.5 million, enhancing investor confidence in long-term growth.

Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerves, announced that CEO Karen Zaderej will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 1:00 p.m. ET. The event will be available for live streaming on Axogen’s Investors page, with a replay accessible for 90 days. Axogen specializes in technologies for nerve regeneration and repair, offering products like Avance® Nerve Graft and Axoguard Nerve Connector® to restore peripheral nerve function, crucial after injuries or surgeries affecting the nervous system.

Axogen, Inc. (NASDAQ: AXGN) has appointed John H. Johnson to its Board of Directors as of July 19, 2021. Johnson brings over 30 years of biopharma experience from senior roles at major companies including Johnson & Johnson and Eli Lilly. He will contribute to both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. CEO Karen Zaderej highlights Johnson's expertise in pipeline strategy and commercial execution as a significant asset for the company’s ongoing commitment to innovation in peripheral nerve repair.

Axogen, Inc. (NASDAQ: AXGN) announced it will report Q2 2021 financial results on August 4, 2021, after market close. Management will host a conference call at 4:30 p.m. ET. Interested investors can participate via phone or listen online through Axogen's website. The company specializes in surgical solutions for peripheral nerve repair, offering products like Avance Nerve Graft and Axoguard Nerve Connector. Axogen aims to improve patient outcomes following peripheral nerve injuries.